Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis.
The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often used to treat Bcc infections in patients with cystic fibrosis. However, Synspira said the microbial agents have demonstrated limited efficacy in the past.
Get the full story at our sister site, Drug Delivery Business News.
The post Synspira’s therapy could boost antibiotics against drug-resistant bacteria in CF patients appeared first on MassDevice.